Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal Diclofenac vs Indomethacin for Post-ERCP Pancreatitis
NCT05947461Terminated
- Sponsor
- Air Force Medical University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of diclofenac in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Air Force Medical University. Primary endpoint: Rate of post-ERCP Pancreatitis at 30 days. Started Jun 2023; status: terminated.
02
Drugs
diclofenac
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT05947461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947461.